AGIO on XNAS, Health Care, Agios Pharmaceuticals, Inc., job postings
Measures activity, not value. Not investment advice.
Quarterly revenue jumped 330% to $55.4M but the company lost $372.9M over 12 months.
BadFree cash flow of -$336M over the last 12 months, cash going out
WatchShares fell 26% in one month; still up 12% over 12 months
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
expected around 11 Feb 2027 (an estimate: a year ago it reported on 12 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $55.4M, net loss $65.0M.
31 Dec 2021RevenueNet incomeNet losstallest bar $947.9M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$55.4M
-$65.0M
30 Jun 2026
$44.7M
-$100.7M
31 Mar 2026
$20.7M
-$99.1M
31 Dec 2025
$20.0M
-$108.0M
30 Sep 2025
$12.9M
-$103.4M
30 Jun 2025
$12.5M
-$112.0M
31 Mar 2025
$8.7M
-$89.3M
31 Dec 2024
$10.7M
-$96.5M
30 Sep 2024
$9.0M
$947.9M
30 Jun 2024
$8.6M
-$96.1M
31 Mar 2024
$8.2M
-$81.5M
31 Dec 2023
$7.1M
-$95.9M
30 Sep 2023
$7.4M
-$91.3M
30 Jun 2023
$6.7M
-$83.8M
31 Mar 2023
$5.6M
-$81.0M
31 Dec 2022
–
$36.5M
30 Sep 2022
$3.5M
-$81.7M
30 Jun 2022
$5.6M
-$91.8M
31 Mar 2022
$832K
-$94.8M
31 Dec 2021
–
-$94.6M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$140.8M
$44.8M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+214%
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$372.9M
-$401.3M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$6.32
-$7.00
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
93.8%
87.2%
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-298%
–
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-265%
-896%
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-32.9%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
-$336.0M
-$414.1M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$907.0M
$1.3B
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$907.0M (net cash)
-$1.3B
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$16.37
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
11.7
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
5.3
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
1.7
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+330%
$55.4M vs $12.9M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
-24%
$1.2M vs $1.6M (quarter ended 30 Sep 2026)
Insider buy/sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$371K
bought $0, sold $371K
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+3.4%
241 13F filers vs 233
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
67.0M shares held by 13F filers (30 Sep 2026) of 59.8M outstanding (30 Oct 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
11%
6.5M shares sold short (30 Oct 2026) of 59.8M outstanding (30 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
5.2
6.5M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-5.4%
6.9M shares sold short in the report before, 6.5M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
44%
44% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 48%
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
$73K
the 12 months before: $0
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$150K
4 quarters
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
11
11 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
11×
11 articles in the last 7 days; its usual week has 1.
Unusual now sharp changes in the last 90 days, compared with its own past
Revenue $55.4M, 4.3× a year earlier
Price $27.60 on 20 Nov 2026, +12% over 12 months (12-month range $24.43 to $44.01)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $4.9M in the last 12 months (the 12 months before: -$4.1M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 10 published in the last 12 months, +25% on the 12 months before.Revenue per quarter. Revenue $55.4M in the latest quarter, +330% on a year earlier.Capital spending per quarter. Capital spending $1.2M in the latest quarter, -24% on a year earlier.Institutional holders (13F filers). 241 13F filers reported holding it in the latest 13F quarter, +15% on a year earlier.Federal obligations. Federal obligations: $73K published in the last 12 months (none in the 12 months before).Lobbying spend. Lobbying spend: $150K published in the last 12 months, +400% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.
Reported lobbying spend: $30K in Q3 2026, $30K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
26 May 2026
New
Gridiron Public Affairs, LLCfor Agios Pharmaceuticals
Issues related to patient access to innovative therapiesHealth issues
The Petrizzo Group, Inc.for Agios Pharmaceuticals, Inc.
Advocated for NIH Federal Funding related to radiation exposure; Advocated for NIH Federal Funding related to radiation exposure.Defense, Budget, Health issues
The Petrizzo Group, Inc.for Agios Pharmaceuticals, Inc.
Advance federal funding for research into cancer metabolism and the development of therapies that disrupt the growth and survival of cancer cells.Health issues, MED
Two or more unrelated kinds of records unusual within 30 days
17 Feb 2026confirmed
Confirmed across sources Filings + Financials and Short interest and volume
Agios Pharmaceuticals(AGIO): had 7.4M shares sold short in the 15 Jan 2026 report, 1.4× the same report last year, while it reported revenue of $20.0M for the quarter ended 31 Dec 2025, 1.9× the same quarter last year. Two unrelated kinds of activity within 14 days.
Short interest and volume: Short interest spike, became public on 28 Jan 2026
Financials: Quarterly revenue change, became public on 17 Feb 2026
The 15 Jan 2026 report against the 24 reports before it.
this reportearliernormal: 4.5MSee the evidence (2 changes)
Short interest and volume: Short interest spike became public on 28 Jan 2026
Agios Pharmaceuticals had 7.4M shares sold short in the 15 Jan 2026 report, 1.4× the same report last year.
This period
7.4M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
4.5M
Typical spread (median absolute deviation)
517K
How far from its usual level
+3.9
Same report last year
5.3M
History used
2,939 days
the 15 Jan 2026 report24 earlier reportsnormal: 4.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 17 Feb 2026
Agios Pharmaceuticals reported revenue of $20.0M for the quarter ended 31 Dec 2025, 1.9× the same quarter last year.
This period
$20.0M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$8.8M
Typical spread (median absolute deviation)
$1.2M
How far from its usual level
+6.3
Same quarter last year
$10.7M
History used
5,023 days
the quarter ended 31 Dec 20258 earlier quartersnormal: $8.8M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
5 Aug 2025confirmed
Confirmed across sources Filings + Financials and Lobbying
Agios Pharmaceuticals(AGIO): lobbying on a new issue, while it reported revenue of $12.5M for the quarter ended 30 Jun 2025, 1.4× the same quarter last year. Two unrelated kinds of activity within 14 days.
Lobbying: Lobbying on a new issue, became public on 22 Jul 2025
Financials: Quarterly revenue change, became public on 5 Aug 2025
The quarter ended 30 Jun 2025 against the 8 quarters before it.
this quarterearliernormal: $8.4MSee the evidence (2 changes)
Lobbying: Lobbying on a new issue became public on 22 Jul 2025
Agios Pharmaceuticals lobbying on a new issue.
New
['MMM', 'PHA']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4821615
Financials: Quarterly revenue change became public on 5 Aug 2025
Agios Pharmaceuticals reported revenue of $12.5M for the quarter ended 30 Jun 2025, 1.4× the same quarter last year.
This period
$12.5M (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
$8.4M
Typical spread (median absolute deviation)
$782K
How far from its usual level
+3.5
Same quarter last year
$8.6M
History used
4,839 days
the quarter ended 30 Jun 20258 earlier quartersnormal: $8.4M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
5 Mar 2019confirmed
Confirmed across sources Filings + Financials and Short interest and volume
Agios Pharmaceuticals(AGIO): reported revenue of $30.0M for the quarter ended 31 Dec 2018, 3.1× the same quarter last year, while it had 7.8M shares sold short in the 28 Feb 2019 report, 1.5× the same report last year. Two unrelated kinds of activity within 21 days.
Financials: Quarterly revenue change, became public on 19 Feb 2019
Short interest and volume: Short interest spike, became public on 28 Feb 2019
Short interest and volume: Short interest spike, became public on 12 Mar 2019
The quarter ended 31 Dec 2018 against the 8 quarters before it.
this quarterearliernormal: $11.4MSee the evidence (3 changes)
Financials: Quarterly revenue change became public on 19 Feb 2019
Agios Pharmaceuticals reported revenue of $30.0M for the quarter ended 31 Dec 2018, 3.1× the same quarter last year.
This period
$30.0M (the quarter ended 31 Dec 2018)
Normal quarter (median of 8 earlier)
$11.4M
Typical spread (median absolute deviation)
$2.1M
How far from its usual level
+6.1
Same quarter last year
$9.8M
History used
2,466 days
the quarter ended 31 Dec 20188 earlier quartersnormal: $11.4M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 28 Feb 2019
Agios Pharmaceuticals had 7.3M shares sold short in the 15 Feb 2019 report, 1.3× the same report last year.
This period
7.3M (the 15 Feb 2019 report)
Normal report (median of 24 earlier)
5.4M
Typical spread (median absolute deviation)
360K
How far from its usual level
+3.6
Same report last year
5.8M
History used
413 days
the 15 Feb 2019 report24 earlier reportsnormal: 5.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Mar 2019
Agios Pharmaceuticals had 7.8M shares sold short in the 28 Feb 2019 report, 1.5× the same report last year.
This period
7.8M (the 28 Feb 2019 report)
Normal report (median of 24 earlier)
5.4M
Typical spread (median absolute deviation)
360K
How far from its usual level
+4.5
Same report last year
5.3M
History used
426 days
the 28 Feb 2019 report24 earlier reportsnormal: 5.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
10 Nov 2026Financials change
reported revenue of $55.4M for the quarter ended 30 Sep 2026, 4.3× the same quarter last year.
Same quarter last year: $12.9M; its normal quarter is $12.7M.
See the evidence
This period
$55.4M (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
$12.7M
Typical spread (median absolute deviation)
$3.8M
How far from its usual level
+7.5
Same quarter last year
$12.9M
History used
5,296 days
the quarter ended 30 Sep 20268 earlier quartersnormal: $12.7M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $44.7M for the quarter ended 30 Jun 2026, 3.6× the same quarter last year.
Same quarter last year: $12.5M; its normal quarter is $11.6M.
See the evidence
This period
$44.7M (the quarter ended 30 Jun 2026)
Normal quarter (median of 8 earlier)
$11.6M
Typical spread (median absolute deviation)
$2.7M
How far from its usual level
+8.1
Same quarter last year
$12.5M
History used
5,204 days
the quarter ended 30 Jun 20268 earlier quartersnormal: $11.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $20.7M for the quarter ended 31 Mar 2026, 2.4× the same quarter last year.
Same quarter last year: $8.7M; its normal quarter is $9.8M.
See the evidence
This period
$20.7M (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
$9.8M
Typical spread (median absolute deviation)
$1.4M
How far from its usual level
+5.1
Same quarter last year
$8.7M
History used
3,652 days
the quarter ended 31 Mar 20268 earlier quartersnormal: $9.8M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 7.4M shares sold short in the 15 Jan 2026 report, 1.4× the same report last year, while it reported revenue of $20.0M for the quarter ended 31 Dec 2025, 1.9× the same quarter last year. Two unrelated kinds of activity within 14 days.
See the evidence (2 changes)
Short interest and volume: Short interest spike became public on 28 Jan 2026
Agios Pharmaceuticals had 7.4M shares sold short in the 15 Jan 2026 report, 1.4× the same report last year.
This period
7.4M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
4.5M
Typical spread (median absolute deviation)
517K
How far from its usual level
+3.9
Same report last year
5.3M
History used
2,939 days
the 15 Jan 2026 report24 earlier reportsnormal: 4.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 17 Feb 2026
Agios Pharmaceuticals reported revenue of $20.0M for the quarter ended 31 Dec 2025, 1.9× the same quarter last year.
This period
$20.0M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$8.8M
Typical spread (median absolute deviation)
$1.2M
How far from its usual level
+6.3
Same quarter last year
$10.7M
History used
5,023 days
the quarter ended 31 Dec 20258 earlier quartersnormal: $8.8M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
17 Feb 2026Financials change
reported revenue of $20.0M for the quarter ended 31 Dec 2025, 1.9× the same quarter last year.
Same quarter last year: $10.7M; its normal quarter is $8.8M.
See the evidence
This period
$20.0M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$8.8M
Typical spread (median absolute deviation)
$1.2M
How far from its usual level
+6.3
Same quarter last year
$10.7M
History used
5,023 days
the quarter ended 31 Dec 20258 earlier quartersnormal: $8.8M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 7.4M shares sold short in the 15 Jan 2026 report, 1.4× the same report last year.
Same report last year: 5.3M; its normal report is 4.5M.
See the evidence
This period
7.4M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
4.5M
Typical spread (median absolute deviation)
517K
How far from its usual level
+3.9
Same report last year
5.3M
History used
2,939 days
the 15 Jan 2026 report24 earlier reportsnormal: 4.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $12.9M for the quarter ended 30 Sep 2025, 1.4× the same quarter last year.
Same quarter last year: $9.0M; its normal quarter is $8.7M.
See the evidence
This period
$12.9M (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
$8.7M
Typical spread (median absolute deviation)
$876K
How far from its usual level
+3.2
Same quarter last year
$9.0M
History used
4,931 days
the quarter ended 30 Sep 20258 earlier quartersnormal: $8.7M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
lobbying on a new issue, while it reported revenue of $12.5M for the quarter ended 30 Jun 2025, 1.4× the same quarter last year. Two unrelated kinds of activity within 14 days.
See the evidence (2 changes)
Lobbying: Lobbying on a new issue became public on 22 Jul 2025
Agios Pharmaceuticals lobbying on a new issue.
New
['MMM', 'PHA']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4821615
Financials: Quarterly revenue change became public on 5 Aug 2025
Agios Pharmaceuticals reported revenue of $12.5M for the quarter ended 30 Jun 2025, 1.4× the same quarter last year.
This period
$12.5M (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
$8.4M
Typical spread (median absolute deviation)
$782K
How far from its usual level
+3.5
Same quarter last year
$8.6M
History used
4,839 days
the quarter ended 30 Jun 20258 earlier quartersnormal: $8.4M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
5 Aug 2025Financials change
reported revenue of $12.5M for the quarter ended 30 Jun 2025, 1.4× the same quarter last year.
Same quarter last year: $8.6M; its normal quarter is $8.4M.
See the evidence
This period
$12.5M (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
$8.4M
Typical spread (median absolute deviation)
$782K
How far from its usual level
+3.5
Same quarter last year
$8.6M
History used
4,839 days
the quarter ended 30 Jun 20258 earlier quartersnormal: $8.4M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 8.0M shares sold short in the 12 Jan 2024 report, 1.2× the same report last year.
Same report last year: 6.7M; its normal report is 5.9M.
See the evidence
This period
8.0M (the 12 Jan 2024 report)
Normal report (median of 24 earlier)
5.9M
Typical spread (median absolute deviation)
143K
How far from its usual level
+3.6
Same report last year
6.7M
History used
2,205 days
the 12 Jan 2024 report24 earlier reportsnormal: 5.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.6M shares sold short in the 15 Nov 2021 report, 1.4× the same report last year.
Same report last year: 5.6M; its normal report is 5.5M.
See the evidence
This period
7.6M (the 15 Nov 2021 report)
Normal report (median of 24 earlier)
5.5M
Typical spread (median absolute deviation)
310K
How far from its usual level
+3.7
Same report last year
5.6M
History used
1,417 days
the 15 Nov 2021 report24 earlier reportsnormal: 5.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 80 entries; narrow the window or the kind of data to see older ones.
Not listed: 398 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001439222
Ticker
AGIO
Domain
agios.com
Employer name
AGIOS PHARMACEUTICALS, INC. (1 unverified)
Hq location
MA|CAMBRIDGE|02139 (1 unverified)
Lobbying client
agios pharmaceuticals
Name
Agios France SARL, Agios Germany GmbH, Agios International Sarl (GmbH), Agios Italy S.R.L and 4 more
Uei
H7M5XL4EHLQ4, KKWAB4MN58M3, ME2BQHBUZJC3
Wikidata
Q16824426
Wikipedia
Agios Pharmaceuticals
DOL H-1B labor condition applications and PERM certifications321 data points1 Oct 2019 to 21 Sep 2026
Federal lobbying disclosures (LDA)7 records, 86 data points1 May 2009 to 30 Sep 2026
SEC Form 13F institutional holdings477 data points30 Sep 2013 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)195 records11 Jan 2016 to 5 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1023 data points31 Dec 2010 to 30 Oct 2026
SEC Form 4 insider transactions246 records, 736 data points5 Jan 2016 to 28 Oct 2026
FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards9 data points7 Feb 2011 to 14 Jul 2026
Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026